Abstract:
The present invention relates to compositions and methods for providing a recombinant thermostable Thermotoga neapolitana alkaline phosphatase enzyme. More particularly, the invention relates to engineering Escherichia coli with T. neapolitana alkaline phosphatase gene expression vectors for providing an inducible system for thermostable enzyme production, wherein the expressed enzyme is readily soluble with a high degree of activity. These methods provide for commercial quantities of a thermostable alkaline phosphatase enzyme.
Abstract:
The present invention relates to compositions and methods utilizing thermostable and novel alcohol dehydrogenase enzymes for biosynthesizing chiral specific molecules for use as precursor molecules in synthesizing pharmaceutical compounds. Particularly, in preferred embodiments, the invention relates to directed engineering of an enzymatic catalytic site of an alcohol dehydrogenase enzyme gene for enhancing enantioselectivity for (S)-enantiomer substrate catalytic activity for providing aryl (S)-enantiomer products in stereomeric excess.
Abstract:
The present invention relates to compositions and methods for providing a recombinant thermostable Thermotoga neapolitana alkaline phosphatase enzyme. More particularly, the invention relates to engineering Escherichia coli with T. neapolitana alkaline phosphatase gene expression vectors for providing an inducible system for thermostable enzyme production, wherein the expressed enzyme is readily soluble with a high degree of activity. These methods provide for commercial quantities of a thermostable alkaline phosphatase enzyme.
Abstract:
A minimal defined medium for growth of A. succinogenes in an anaerobic environment is described. The medium expands the experimental opportunities for studying the metabolism of A. succinogenes, including 13 C-labeling experiments . The medium comprises essential amino acids . Other ingredients are also essential such as glucose or another carbohydrate as the primary carbon source, minerals, and vitamins . The medium allows for 13 C-labelling experiments that can reveal the metabolic pathways used by A. succinogenes and the extent to which they are used, including those pathways involved in succinate production
Abstract:
A pneumatic bioreactor includes a vessel containing a fluid to be mixed and at least one mixing device driven by gas pressure. A first embodiment includes a floating impeller that rises and falls In the fluid as gas bubbles carry it upward to the surface where the gas is then vented, permitting the impeller to sink in the fluid. The floating impeller may be tethered to a second impeller with a flexible member and pulley. The mixing speed is controlled with electromagnets in the vessel acting upon magnetic material in the impeller or its guides. In another embodiment, floating pistons mix the fluid, pushing it through a mixing plate with one or more apertures. In a third embodiment, the mixing device is a rotating drum vvith bubble-catching blades and rotating mixing plates with apertures. The top of the vessel for these mixers may include a closed top and sterile filters.
Abstract:
A pneumatic bioreactor having a containment vessel which includes a semi-cylindrical concavity defined by the vessel bottom. A mixing apparatus includes a rotational mixer rotatably mounted within the containment vessel about a horizontal axis. The rotational mixer has buoyancy-driven mixing cavities which are fed by a gas supply beneath the rotational mixer. The mixing apparatus extends into the semi- cylindrical concavity to substantially fill that concavity. The rotational mixer is divided into two wheels with outer paddles extending axially outwardly and inner paddles extending axially inwardly on either side of each ring. Blades between the outer and inner paddles form impellers in the wheels to induce axial flow through the rings in opposite directions. The containment vessel may be of film and supported by a structural housing also having a semi-cylindrical concavity defined by the housing bottom.
Abstract:
The present invention relates to compositions and methods utilizing thermostable and novel alcohol dehydrogenase enzymes for biosynthesizing chiral specific molecules for use as precursor molecules in synthesizing pharmaceutical compounds. Particularly, in preferred embodiments, the invention relates to directed engineering of an enzymatic catalytic site of an alcohol dehydrogenase enzyme gene for enhancing enantioselectivity for (S)-enantiomer substrate catalytic activity for providing aryl (S)-enantiomer products in stereomeric excess.
Abstract:
A pneumatic bioreactor includes a vessel containing a fluid to be mixed and at least one mixing device driven by gas pressure. A first embodiment includes a floating impeller that rises and falls In the fluid as gas bubbles carry it upward to the surface where the gas is then vented, permitting the impeller to sink in the fluid. The floating impeller may be tethered to a second impeller with a flexible member and pulley. The mixing speed is controlled with electromagnets in the vessel acting upon magnetic material in the impeller or its guides. In another embodiment, floating pistons mix the fluid, pushing it through a mixing plate with one or more apertures. In a third embodiment, the mixing device is a rotating drum vvith bubble-catching blades and rotating mixing plates with apertures. The top of the vessel for these mixers may include a closed top and sterile filters.
Abstract:
Actinobacillus succinogenes genes and methods of using the genes in genetically engineered A. succinogenes so as to improve production of chemicals such as succinate, fumarate, malate, 5-aminolevulinate, 2-oxoglutarate, glutamate, and aspartate. The genetically engineered A. succinogenes strains are capable of overexpressing C4 enzymes. The genetically engineered A. succinogenes can have one or more gene knockouts or modifications that inhibit C3 enzymes. The fluxes supplying substrate to the C4 pathway can also be improved in some of the genetically engineered A. succinogenes.
Abstract:
Actinobacillus succinogenes genes and methods of using the genes in genetically engineered A. succinogenes so as to improve production of chemicals such as succinate, fumarate, malate, 5-aminolevulinate, 2-oxoglutarate, glutamate, and aspartate. The genetically engineered A. succinogenes strains are capable of overexpressing C4 enzymes. The genetically engineered A. succinogenes can have one or more gene knockouts or modifications that inhibit C3 enzymes. The fluxes supplying substrate to the C4 pathway can also be improved in some of the genetically engineered A. succinogenes.